StockNews.com upgraded shares of Jaguar Health (NASDAQ:JAGX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday.
Jaguar Health Stock Performance
Jaguar Health stock opened at $4.26 on Friday. The business’s 50-day simple moving average is $5.49 and its 200 day simple moving average is $6.52. The company has a current ratio of 1.89, a quick ratio of 1.39 and a debt-to-equity ratio of 1.84. Jaguar Health has a 12-month low of $3.07 and a 12-month high of $41.76.
Jaguar Health (NASDAQ:JAGX – Get Free Report) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($3.60) earnings per share (EPS) for the quarter. The business had revenue of $2.35 million during the quarter. Jaguar Health had a negative net margin of 377.95% and a negative return on equity of 642.15%. On average, equities analysts predict that Jaguar Health will post -5.42 EPS for the current fiscal year.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
See Also
- Five stocks we like better than Jaguar Health
- Dividend Payout Ratio Calculator
- Why This AI Stock is Rising Despite Tech Sell-Off
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
- Financial Services Stocks Investing
- MarketBeat Week in Review – 7/15 – 7/19
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.
